 Myriads MyRiskTM Hereditary Cancer test with RiskScore provides a personalized breast cancer risk assessment for women of all ancestries SALT LAKE CITY, Dec. 08, 2022 GLOBE NEWSWIRE Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate ... The post Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Pre... 